C-rad Ab Class B · OMXSTO:CRAD_B
C-rad Ab Class B — Q3 2026 Earnings Presentation
19 slides from C-rad Ab Class B's earnings presentation, Oct 22, 2026
Slide 1: C-RAD Q3 Report
C-RAD Q3 Report Tomas Blomquist, CEO Linda Frölén, CFO Eeva-Liisa Karjalainen, CPTO
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements regarding operational and financial performance, market conditions, and related matters. These statements reflect current expectations and are believed to be reasonable, but they are not guarantees — actual results may differ materi
Slide 3: Q3 highlights
Q3 highlights ORDER INTAKE -40% 49 -34% Q3’25 40 Order intake Q3’26 +20% 29 SEK 76m (106), down 29% year-on-year 27 20 17 Revenue SEK 85m (112), down 24% year-on-year Americas EMEA APAC Record service revenue SEK 30m, the highest quarterly level ever REVENUE -23% -33% 49 Q3’25 44 Resilient profitabi
Slide 4: Strategic progress in Q3
Strategic progress in Q3 CUSTOMERS PL AT FORM T RANSFORMAT ION Strategic customer Progress towards open Transformation is on wins workflow platform track New business with Ron-Ergea Advancements in automated Strengthened commercial in Germany, building on patient identification and organisation, inc
Slide 5: Financial update
Financial update Linda Frölén, CFO
Slide 6: Gross profit & gross margin
Gross profit & gross margin GROSS PROFIT & GROSS MARGIN BY QUARTER, LTM Gross margin Gross profit Gross profit Q3’26 64.9 (82.8) MSEK 350 74 mSEK % 72 Gross margin Q3’26 300 70 76 (74) % 68 250 66 200 64 Positive contribution from higher margin service 62 revenue and favourable product mix 150 60
Slide 7: Continued cost control, Q3 affected by summer holidays
Continued cost control, DEVELOPMENT YoY & QoQ Q3 affected by summer holidays YoY* QoQ* -9% -7% 60 58 54 54 Development year-on-year Average no of FTEs down 23 23 23 23 Commissions lower following the lower order intake and revenue. Capitalization rate also increased as product development pace has i
Slide 8: Q3 EBIT strained from revenue drop, partly offset by higher gross margin and lower expenses
Q3 EBIT strained from EBIT & EBIT MARGIN, LTM revenue drop, partly offset by EBIT margin % EBIT, mSEK higher gross margin and lower expenses 80 mSEK % 24 70 22 20 EBIT Q3’26: 60 18 9.9 (21.2) MSEK 16 50 14 EBIT margin Q3’26: 40 12 12 (19) % 30 10 8 20 6 4 10 2 0 0 *) excluding non-recurring costs re
Slide 9: Improved cash balance & a strong balance sheet
Improved cash balance & CASH BALANCE & OPERATING CASH FLOW, LTM a strong balance sheet Cash balance Operating cash flow* 180 Cash balance increased 6 MSEK from 138 160 mSEK MSEK at end of previous quarter to144 MSEK 140 end of Q3 120 Operating cash flow 9.4 (24.4) MSEK 100 Cash flow from worki
Slide 10: Increased pace in product development
Increased pace in product development Accelerating product development through INVESTMENTS IN PRODUCT DEVELOPMENT, LTM increased investments 24 +16 Yearly investments increased by approximately SEK 16 mSEK million 22 20 18 Scaling up innovation to strengthen our 16 competitive position 14 Increased
Slide 11: Product update
Product update Eeva-Liisa Karjalainen, CPTO
Slide 12: Enhancing cancer care with Surface Guided Radiotherapy
Enhancing cancer care with Surface Guided Radiotherapy A C C U R AC Y. E F F I C I E N C Y. S A F E T Y. Together with clinicians, we combine technology and care to make every patient journey safer and better. Treating a tumour demands precision: targeting cancer effectively while protecting surroun
Slide 13: Building from a great position in the treatment workflow
Building from a great position in the treatment workflow SOLUT IONS POSI T IONED AT T HE HEART OF T HE WORKFLOW Sentinel 4DCT Catalyst⁺ HD The Starting Point The Eyes Capture the patient's surface Track real-time patient for precise treatment setup. movement in treatment. Simulation Plan Patient set
Slide 14: Showcasing product updates at ASTRO – SGRT
Showcasing product updates at ASTRO – SGRT Successful ASTRO congress in Boston September 27-29 to showcase C-RAD’s latest product updates Preview of the upcoming major product release of flagship surface scanning product Catalyst⁺ HD Showcasing of the newest addition to the product family, the
Slide 15: Towards a category leading open oncology workflow platform
Towards a category leading open oncology workflow platform T H R E E L AY E R S O F C - R A D ’ S E C O S Y S T E M Strengthen the core Build Evolution and refinement of C-RAD software and hardware SGRT solutions with enhanced usability and interoperability in focus Expand the value Build Partner Ne
Slide 16: Demonstrating the first steps of the expanded portfolio at ASTRO
Demonstrating the first steps of the expanded portfolio at ASTRO CONNECT ING AND UNIF YING ONCOLOGY WORK F LOWS First preview of the upcoming workflow automation solutions from C-RAD was showcased at ASTRO Automated patient identity verification solution with state-of-the-art facial recognition
Slide 17: Different perspectives. Shared purpose. Open interfaces.
Different perspectives. Shared purpose. Open interfaces. P A R T N E R S H I P I S N O T A T A C T I C ; I T ’ S H O W W E I N N O VA T E We bring technical expertise, our partners bring theirs. Together, we innovate at the intersection of what is technically possible and clinically valuable. Always
Slide 18: First ecosystem partner: SeeTreat
First ecosystem partner: SeeTreat RA DIAT I ON ON COLOGY N EE DS CON NECT ED S YS T E M S, NOT ISOLAT ED TOOLS SeeTreat is an Australian med tech company that provides decision support for adaptive radiotherapy workflows C-RAD and SeeTreat have entered a partnership to co-develop and commerciali
Slide 19: Q&A
Q&A